Muutke küpsiste eelistusi

WHO reporting system for Pancreaticobiliary Cytopathology [Pehme köide]

  • Formaat: Paperback / softback, 200 pages, kõrgus x laius: 270x203 mm, kaal: 653 g, col. ill.
  • Sari: WHO Reporting Systems for Cytopathology 2
  • Ilmumisaeg: 05-Apr-2023
  • Kirjastus: IARC
  • ISBN-10: 9283245180
  • ISBN-13: 9789283245186
Teised raamatud teemal:
  • Formaat: Paperback / softback, 200 pages, kõrgus x laius: 270x203 mm, kaal: 653 g, col. ill.
  • Sari: WHO Reporting Systems for Cytopathology 2
  • Ilmumisaeg: 05-Apr-2023
  • Kirjastus: IARC
  • ISBN-10: 9283245180
  • ISBN-13: 9789283245186
Teised raamatud teemal:
WHO Reporting System for Pancreaticobiliary Cytopathology is Volume 2 of this new series of reporting systems for cytopathology, which is a joint project of the International Academy of Cytology (IAC) and the International Agency for Research on Cancer (IARC), a specialized agency of the World Health Organization (WHO). The series includes a unique synthesis of the published evidence and the practice of cytopathology, and it is linked to the WHO Classification of Tumours series, now in its 5th edition.

Cytopathologists look at tumours slightly differently than other specialists do, and there is a need for specialized reporting systems based on the key diagnostic cytopathological features of tumours, presented in standardized reports, within a hierarchical system of diagnostic categories. These categories must also be linked to diagnostic management recommendations to improve communication with clinicians and support patient care. And it is essential that these reporting systems be truly international, to serve the needs of patients worldwide in many differently medically resourced settings.

These volumes are an essential tool for standardizing diagnostic cytopathology practice worldwide and will serve as a vehicle for the translation of cytopathology research into practice. The key diagnostic cytopathological features are listed for each tumour type under a defined set of diagnostic categories and described in precise, uniform language. These diagnostic criteria represent the first international consensus and are underpinned by evidence that has been evaluated and debated by experts in the field. Each lesion-specific section includes a dedicated subsection discussing the differential diagnosis of the cytopathological features that can be usedthroughout the world, including in low-resource settings, followed by a subsection describing the current best-practice application of ancillary testing (including next-generation sequencing) on cytopathology material.

This volume:
  • Prepared by about 70 authors and editors
  • Contributors from around the world, reflecting an international expertise
  • Hundreds of high-quality images
  • More than 900 references
List of abbreviations
viii
Foreword ix
1 Introduction to the WHO Reporting System for Pancreati-cobiliary Cytopathology
1(10)
Background
2(2)
The role of pancreaticobiliary cytopathology
4(1)
Integration of clinical, radiological, and key FNAB cytopathological features with ancillary testing in a diagnostic approach
5(1)
Diagnostic categories and report structure
6(3)
Risk of malignancy and management recommendations
9(2)
2 Pancreaticobiliary cytopathology techniques
11(20)
Sampling methods and tissue triage FNAB techniques and specimen management for solid pancreatic masses
12(1)
FNAB techniques and specimen management for pancreatic cysts
13(1)
FNAB techniques and specimen management for bile duct brushings
14(2)
Percutaneous FNAB and specimen management
16(1)
Rapid onsite evaluation
17(1)
Ancillary testing Introduction: The role of ancillary testing
18(1)
Immunocytochemistry
19(4)
In situ hybridization
23(3)
Molecular testing
26(3)
Biochemical testing of cyst fluid
29(2)
3 Diagnostic category: Insufficient/Inadequate/Non-diag-nostic
31(6)
Introduction
32(1)
Definition
32(1)
Discussion and background
33(2)
Risk of malignancy and management recommendations
35(1)
Sample reports
36(1)
4 Diagnostic category: Benign / Negative for malignancy
37(34)
Introduction
38(1)
Definition
38(1)
Discussion and background
39(1)
Risk of malignancy and management recommendations
40(1)
Benign non-neoplastic processes Normal pancreatic and biliary parenchyma and contaminants
41(3)
Acute pancreatitis
44(2)
Cholangitis
46(2)
Chronic pancreatitis
48(2)
Groove/paraduodenal pancreatitis
50(2)
Autoimmune and lgG4-related pancreatitis
52(3)
Lymphoepithelial cyst
55(2)
Pseudocysts
57(2)
Splenule (accessory spleen)
59(2)
Benign neoplastic processes Serous cystadenoma
61(3)
Schwannoma
64(1)
Lymphangioma
65(1)
Other rare benign neoplasms
66(1)
Sample reports
67(4)
5 Diagnostic category: Atypical
71(6)
Introduction
72(1)
Definition
72(1)
Discussion and background
73(2)
Risk of malignancy and management recommendations
75(1)
Sample reports
76(1)
6 Diagnostic category: Pancreaticobiliary neoplasm, low-risk/grade
77(16)
Introduction
78(1)
Definition
78(1)
Discussion and background
79(1)
Risk of malignancy and management recommendations
80(1)
Specific lesions Pancreatic intraepithelial neoplasia, low-grade
81(2)
Biliary intraepithelial neoplasia, low-grade
83(2)
Pancreatic intraductal papillary mucinous neoplasm, low-grade
85(2)
Intraductal papillary neoplasm of the bile duct, low-grade
87(1)
Mucinous cystic neoplasm, low-grade
88(2)
Other lesions (including spindle cell tumours)
90(1)
Sample reports
91(2)
7 Diagnostic category: Pancreaticobiliary neoplasm, high-risk/grade
93(22)
Introduction
94(1)
Definition
94(1)
Discussion and background
95(1)
Risk of malignancy and management recommendations
96(1)
Specific lesions Pancreatic intraepithelial neoplasia, high-grade
97(2)
Biliary intraepithelial neoplasia, high-grade
99(2)
Pancreatic intraductal papillary mucinous neoplasm, high-grade
101(3)
Intraductal papillary neoplasm of the bile duct, high-grade
104(2)
Mucinous cystic neoplasm, high-grade
106(2)
Intraductal oncocytic papillary neoplasm
108(2)
Intraductal tubulopapillary neoplasm
110(2)
Sample reports
112(3)
8 Diagnostic category: Suspicious for malignancy
115(6)
Introduction
116(1)
Definition
116(1)
Discussion and background
117(2)
Risk of malignancy and management recommendations
119(1)
Sample reports
120(1)
9 Diagnostic category: Malignant
121(48)
Introduction
122(1)
Definition
122(1)
Discussion and background
123(1)
Risk of malignancy and management recommendations
124(2)
Specific lesions Cholangiocarcinoma
126(4)
Pancreatic ductal adenocarcinoma
130(9)
Pancreatic acinar cell carcinoma
139(3)
Neuroendocrine tumour
142(4)
Neuroendocrine carcinoma
146(2)
Pancreatoblastoma
148(3)
Solid pseudopapillary neoplasm
151(5)
Pancreatic lymphomas
156(3)
Metastases to the pancreas
159(4)
Other lesions (including spindle cell tumours)
163(3)
Sample reports
166(3)
10 Management recommendationsfor each diagnostic category
169(18)
Introduction
170(1)
Insufficient/Inadequate/Non-diagnostic
171(1)
Benign / Negative for malignancy
172(1)
Atypical
173(1)
Pancreaticobiliary neoplasm, low-risk/grade
174(2)
Pancreaticobiliary neoplasm, high-risk/grade
176(2)
Suspicious for malignancy
178(1)
Malignant
179(2)
Contributors
181(2)
Declaration of interests
183(2)
Sources
185(2)
References 187(16)
Subject Index 203(2)
Previous volumes in the series 205